An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.
Harper J, Adams KJ, Bossi G, Wright DE, Stacey AR, Bedke N, Martinez-Hague R, Blat D, Humbert L, Buchanan H, Le Provost GS, Donnellan Z, Carreira RJ, Paston SJ, Weigand LU, Canestraro M, Sanderson JP, Botta Gordon-Smith S, Lowe KL, Rygiel KA, Powlesland AS, Vuidepot A, Hassan NJ, Cameron BJ, Jakobsen BK, Dukes J.
Harper J, et al. Among authors: canestraro m.
PLoS One. 2018 Oct 15;13(10):e0205491. doi: 10.1371/journal.pone.0205491. eCollection 2018.
PLoS One. 2018.
PMID: 30321203
Free PMC article.